ArQule Announces Orphan Drug Designation in Cholangiocarcinoma and Clinical Update for ARQ 087
December 15, 2015 07:30 ET | ArQule, Inc.
Orphan drug designation marks significant regulatory milestone for phase 2 trialAdditional response in phase 1b further validates development for ARQ 087 in cancers with FGFR2 genetic alterations ...